Systematic review and meta-analysis of endometrial thickening during endocrine therapy combined with Chinese herbal medicine intervention after breast cancer surgery

Objective:To systematically evaluate the endometrial thickening and Chinese herbal medicine intervention effects during endocrine therapy following breast cancer surgery.Methods:Computerized searches were performed on CNKI,CBM,Wanfang,VIP,Pub Med,Embase,and Cochrane to gather randomized controlled trials(RCTs)of endometrial thickening combined with Chinese herbal medicine intervention during endocrine therapy after breast cancer surgery.The meta analysis is done using Rev Man 5.4,and the retrieval range is from the database's creation to January 2023.Results:There were 710 patients enrolled in a total of 12 RCTs.The results of Meta-analysis were as follows:combined with Chinese herbal medicine treatment for 3 months of endometrial thickness(MD=-1.12,95%CI[-1.47,0.77],P<0.00001);6 months endometrial thickness(MD=-1.90,95%CI[-2.38,-1.42],P<0.00001);endometrial thickness at 12 months(MD=-2.24,95%CI[-2.96,-1.52],P<0.00001);modified Kupperman score(MD=-10.45,95%CI[-19.10,-1.80],P=0.02);TCM syndrome score(SMD=-1.53,95%CI[-1.84,-1.22],P<0.00001);KPS score(MD=3.75,95%CI[2.81,4.68],P<0.00001);there was no significant difference in CA153,CEA,FSH and E2 between the two groups.Conclusion:After breast cancer surgery,endocrine therapy combined with Chinese herbal medicine can significantly lessen endometrial thickening and enhance patient quality of life.

Integration of Chinese herbal medicines and exercise for insomnia:a systematic review and meta-analysis

Background:As a disease,insomnia is often ignored by the general public.Insomnia,which not directly fatal,may be equivalent to chronic suicide if it is not paid attention to.However,there are many theories on how to treat insomnia,and researchers have been searching for a cure.Chinese herbal medicine(CHM)and exercise therapy(ET)are relatively effective,and have been used since ancient times to treat insomnia.This study aimed to examine the effect of CHM combined with ET(CHM-ET)on patients with insomnia.Methods:We searched eight electronic databases including PubMed,Web of Science,EMBASE,the Cochrane Library,the China National Knowledge Infrastructure(CNKI),the China Biology Medicine disc(CBMdisc),the China Science and Technology Journal Database(VIP),the Wanfang Database to find randomized controlled trials(RCTs)evaluating CHM-ET in the treatment of insomnia patients up to September 13,2022.Two researchers read and screened the publications to extract data.We used the pittsburgh sleep quality index(PSQI)as the evaluation indicators for each study,and the other was the total effective rate(TER).The Cochrane risk-of-bias assessment tool was used to assess the risk of bias of the included literature.The level of evidence for this result was assessed by GARDE method.The meta-analysis was performed using STATA 14 software and RevMan 5.3.The research method was registered with PROSPERO(CRD42022350926).Results:We included fourteen randomized controlled trials,which including a total of 1,126 participants.Compared with the control group,the experimental group showed significantly improvements in sleep effect as reflected by the reduced PSQI score[mean difference(MD)=-2.47,95%confidence interval(CI)(-3.15,-1.78),I^(2)=92%]with low quality of evidence,and increased TER[risk ratio(RR)=1.23,95%CI(1.14,1.33),I^(2)=40%]with moderate quality of evidence.Compared with hypnotic drugs,CHM-ET significantly reduced the PSQI score[mean difference(MD)=-3.18,95%CI(-5.48,-0.89),I^(2)=73%]with low quality of evidence.The PSQI of CHM-ET significantly decreased compared with single CHM[mean difference(MD)=-3.04,95%CI(-5.84,-0.25),I^(2)=98%]with low quality of evidence,and ET[mean difference(MD)=-2.44,95%CI(-2.87,-2.02),I^(2)=0%]with moderate quality of evidence.No serious adverse reactions were observed.Conclusion:This review suggested that CHM-ET may be an effective treatment for insomnia.However,given the limited quality of the studies and methodologies included in the trials,further rigorous randomized controlled trials are needed for more accurate results.

Use of Chinese Herbal Medicine Therapies in Comprehensive Hospitals in Central China: A Parallel Survey in Cancer Patients and Clinicians

Summary： Chinese herbal medicine （CHM）, as the largest application category of traditional Chinese medicine （TCM）, is widely accepted among cancer patients in China. Herbal slice （HS） and Chinese patent drug （CPD） are commonly used CHM in China. This study aimed to investigate the utilization of CHM among clinicians and cancer patients in central China. Five hundred and twenty-five patients and 165 clinicians in 35 comprehensive hospitals in central China were asked to complete an anonymous questionnaire that was designed to evaluate the use of CHM. The results showed that 90.74% clinicians and 72.24% cancer patients used CHM during cancer treatment. The educational backgrounds of the clinicians and the age, education level, annual income, and cancer stage of the cancer patients were re- lated to use of CHM. More than 90% clinicians and cancer patients had used CPD. Comparatively, the percentage of HS use was 10% lower than that of CPD use among clinicians and cancer patients. More clinicians preferred to use CHM after surgery than cancer patients did （20.41% vs. 5.37%）. Enhancing physical fitness and improving performance status were regarded as the most potential effect of CHM on cancer treatment （85.71% among clinicians and 94.07% among cancer patients）, in comparison with directly killing tumor cells （24.49% among clinicians and 31.36% among patients）. As for refusal rea- sons, imprecise efficacy was the unanimous （100%） reason for clinicians＇ rejection of CHM, and 95.58% patients objected to using CHM also for this reason. Furthermore, the side effects of CHM were more concerned by clinicians than by patients （33.33% vs. 15.81%）. In conclusion, our survey revealed that CHM was popularly accepted by clinicians and cancer patients in central China. The reasons of use and rejection of CHM were different between clinicians and cancer patients.

Traditional Chinese herbal medicine plus triple therapy in treating Helicobacter pylori-induced chronic atrophic gastritis: a meta-analysis and cumulative meta-analysis

Objectives:To evaluate the benefits of traditional Chinese herbal medicine(TCHM)plus triple therapy(TT)in the management of Helicobacter pylori(H.pylori)-induced chronic atrophic gastritis(CAG).Methods:A comprehensive access and electronic database search were carried out from inception to June 2020.Prospective randomized trials(TCHM plus TT vs.TT)were selected to assess the eradication rate of H.pylori(ER of H.pylori),clinical symptom relief rate(SRR),treatment-related adverse reactions(TRAR)and 95%confidence intervals(CI)in the meta-analysis and cumulative meta-analysis(CMA).Meta-regression analysis was used to analyze heterogeneity between studies and publication bias.Results:33 studies contained 3,226 participants were included.Compared with the TT group,TCHM plus TT group showed a significantly higher ER of H.pylori(OR=4.14,95%CI:3.21-5.35;P=0.000)and SRR(OR=4.50,95%CI:3.59-5.64).Meanwhile,the TRAR of TCHM plus TT remedy was significantly lower than TT monopoly(RR=0.43,95%CI:0.29-0.64;P=0.000).The results of the CMA,sorted by publication year,duration of treatment,and sample size,confirmed that combined treatment remedy was superior to TT monopoly in respect of ER of H.pylori and SRR.Conclusions:The present study obtained reliable and convincing evidence suggesting that TCHM plus TT remedy was efficacious and safe in treating H.pylori-induced CAG.

Therapeutic potential of natural compounds from Chinese medicine in acute and subacute phases of ischemic stroke

Stroke is one of the leading causes of death and disability in adults worldwide,resulting in huge social and financial burdens.Extracts from herbs,especially those used in Chinese medicine,have emerged as new pharmaceuticals for stroke treatment.Here we review the evidence from preclinical studies investigating neuroprotective properties of Chinese medicinal compounds through their application in acute and subacute phases of ischemic stroke,and highlight potential mechanisms underlying their therapeutic effects.It is noteworthy that many herbal compounds have been shown to target multiple mechanisms and in combinations may exert synergistic effects on signaling pathways,thereby attenuating multiple aspects of ischemic pathology.We conclude the paper with a general discussion of the prospects for novel natural compound-based regimens against stroke.

Integrative techniques using acupuncture,Chinese herbal medicine,diet,and supplements for polycystic ovary syndrome:a case report

Patients with a diagnosis of polycystic ovary syndrome （PCOS） are on the rise. About 4%-12% of women are currently estimated to have this condition. It is hypothesized that PCOS appears in women who have long-standing insulin resistance （1R）, which leads to high androgen and testosterone levels; this ultimately disrupts their menstrual cycles. Some researchers attribute IR to genetic factors, although there have been only minute changes in the human genome in the past 20 000 years. However, even with a stable gene pool, genes can be turned on and offby the environment, food and air quality and toxin exposure.

The roles of traditional Chinese herbal medications in regulating mitochondrial activity to reverse cancer

Cancer was gradually regarded as a metabolic disease,which might be linked to impairment of mitochondrial function.There are really some essential differences between the mitochondria of normal and cancer cells,which might become promising target for cancer chemotherapy.According to western pharmacology,a known target was needed for drug development.Unfortunately,the number of therapeutic agents relating to the mitochondrion are severely limited because of lacking of knowledge about mitochondrial biology.Unlike the“Western Medicine”,some traditional Chinese herbal medicine(TCHM)might be prone to targeting mitochondria despite the lack of precise molecular mechanisms.If it is the case,we might be able to screen and identify active anti-cancer drugs from traditional Chinese therapeutics by using mitochondrial functional assay.In this review,we would give an overview of the effect of TCHM on the mitochondrion,and the challenges and breakthroughs remaining in cancer treatment.

Efficacy of Shugan Hewei Therapy for Chronic Atrophic Gastritis:A Systematic Review and Meta-Analysis

Objective:Shugan Hewei therapy(SHT)acts to soothe the liver and harmonize the stomach.It is a classical traditional Chinese medicine method widely used in China to treat chronic atrophic gastritis(CAG)due to liver qi invading the stomach.However,the clinical effects of SHT remain unclear.We aimed to evaluate the overall clinical effective rate and safety of SHT in treating CAG.Methods:We used the Jadad scale and Cochrane Collaboration risk of bias tool to evaluate the methodological quality of studies investigating SHT.Eight medical databases were searched to identify relevant studies.After data extraction and quality evaluation,27 randomized controlled trials,including 2,441 patients,were considered eligible for analysis.No serious heterogeneity or publication bias was observed across the included studies.We used Revman 5.3 statistical software to evaluate the general clinical effective rate and safety of SHT.Results:The results showed that SHT was more effective(RR=1.25;95%CI[1.20,1.29];P<0.01)and safer(MD=0.24,95%CI[0.08,0.75];P<0.01)than control interventions comprising western medicine,Chinese patent medicine,and/or western medicine+Chinese patent medicine.Compared with the control interventions,SHT resulted in greater improvements in the symptom scores for stomach distension and stomachache,serum gastrin level,histopathologic changes,Helicobacter pylori(HP)inhibition rate,and gastric mucosal inflammation.Conclusion:SHT was more effective and safer than control interventions for CAG.

Therapeutic potential and mechanism of Chinese herbal medicines in treating fibrotic liver disease

Liver fibrosis is a pathological condition characterized by replacement of normal liver tissue with scar tissue,and also the leading cause of liver-related death worldwide.During the treatment of liver fibrosis,in addition to antiviral therapy or removal of inducers,there remains a lack of specific and effective treatment strategies.For thousands of years,Chinese herbal medicines(CHMs)have been widely used to treat liver fibrosis in clinical setting.CHMs are effective for liver fibrosis,though its mechanisms of action are unclear.In recent years,many studies have attempted to determine the possible mechanisms of action of CHMs in treating liver fibrosis.There have been substantial improvements in the experimental investigation of CHMs which have greatly promoted the understanding of anti-liver fibrosis mechanisms.In this review,the role of CHMs in the treatment of liver fibrosis is described,based on studies over the past decade,which has addressed the various mechanisms and signaling pathways that mediate therapeutic efficacy.Among them,inhibition of stellate cell activation is identified as the most common mechanism.This article provides insights into the research direction of CHMs,in order to expand its clinical application range and improve its effectiveness.

A traditional Chinese herbal medicine compound preparation versus interventional therapy after resection of small hepatocellular carcinoma:22-year follow-up

OBJECTIVE:To compare the long-term effectiveness of compound Ruanjianhugan(RJH)tablets and interventional therapy(IT) in patients after resection of small hepatocellular carcinoma(HCC).METHODS:A retrospective study was conducted in 399 patients after resection of small HCC who were admitted between January 1987 and December 2008 in the Department of Hepatobiliary Surgery and Center of Minimlly Invasive Surgery,First Affiliated Hospital of Guangxi Medical University.Four groups were based on different therapy modes:a TCM-only(TCMO) group,a TCM combined with interventional therapy(TCM-IT) group,an interventional therapy-only(ITO) group,and a simple operation(SO) group.Prognostic factors were correlated with overall survival(OS) and OS rates were calculated with the Kaplan-Meier method,and multivariate analyses for factors affecting survival were evaluated by the Cox proportional hazard model.RESULTS:The median OS was 151.20 months in the TCM-IT group,43.87 months in the ITO group,and 20.77 months in the SO group.All survival rates of the TCMO group were higher than those of the other three groups(>50%).The 5-,10-,and 15-year OS in the TCMO and ITO patients were 83.94%,45.50%,and 71.22% and 33.34%,55.58%,and 9.26%,respectively(risk ratio,0.209;95% confidence interval,0.126-0.347;P=0.000).Multivariate analysis revealed that the independent risk factors were therapy mode(P=0.000),sex(P=0.005),family history(P=0.011),TNM Classification of Malignant Tumor staging(P=0.000),medical care-seeking behavior(P=0.021),and maximum diameter(P=0.030).CONCLUSION:Long-term oral use of compound RJH tablets may improve OS for small HCC after resection compared with IT.

Colonic Dialysis Therapy of Chinese Herbal Medicine in Abstinence of Heroin Addicts-Report of 75 Cases

Ｃｏｌｏｎｉｃ Ｄｉａｌｙｓｉｓ Ｔｈｅｒａｐｙ ｏｆ Ｃｈｉｎｅｓｅ Ｈｅｒｂａｌ Ｍｅｄｉｃｉｎｅ ｉｎ Ａｂｓｔｉｎｅｎｃｅ ｏｆ Ｈｅｒｏｉｎ Ａｄｄｉｃｔｓ－Ｒｅｐｏｒｔ ｏｆ ７５ ＣａｓｅｓＳＨＡＬｉ－ｊｕｎ；ＺＨＡＮＧＺｈｉ－ｘｉａｎ...

火针疗法联合消疮散中药面膜治疗面部寻常痤疮的疗效观察

目的:观察火针疗法联合消疮散中药面膜治疗面部寻常痤疮的临床疗效和安全性。方法:选取面部寻常痤疮患者66例,根据纳入标准制定随机对照表,随机分为治疗组(针药联合)和对照组(火针),治疗后,两组实际各纳入31例、32例。火针治疗每周1次,中药面膜治疗隔日1次,疗程均为4周,分别于治疗第2周末、第4周末进行疗效判定,并记录治疗过程中发生的不良反应,疗程结束后1个月对患者进行回访。结果:治疗2周后,两组患者的皮损评分均低于治疗前(P<0.05)。且治疗4周后,治疗组皮损评分低于对照组(P<0.05)。治疗组总有效率96.77%,高于对照组的78.13%(P<0.05)。结论:火针疗法联合消疮散中药面膜治疗面部寻常痤疮疗效确切,安全性高,临床可推广应用。

针刺结合中药保留灌肠对溃疡性结肠炎的疗效及免疫功能的影响

目的:探讨针刺结合中药保留灌肠治疗溃疡性结肠炎(UC)的临床疗效及其改善免疫功能的作用。方法:选取符合纳入标准的UC患者70例,依据随机数字表随机分为观察组和对照组,各35例。对照组给予美沙拉嗪缓释片,观察组在对照组基础上加用针刺与中药保留灌肠疗法,两组均治疗8周。比较两组患者治疗前后血清免疫功能指标CD3^(+)、CD4^(+)与CD8^(+)含量、炎症因子指标白细胞介素(IL)-1β、IL-23与转化生长因子-β1(TGF-β1)的改善情况。结果:治疗后,两组患者TGF-β1、CD3^(+)、CD4^(+)含量均较治疗前明显升高(P<0.05),IL-1β、IL-23、CD8^(+)含量下降(P<0.05);且观察组治疗后TGF-β1、CD3^(+)和CD4^(+)水平均高于对照组(P<0.05),IL-1β、IL-23、CD8^(+)水平均低于对照组(P<0.05)。结论:针刺结合中药保留灌肠治疗能显著改善UC患者免疫功能,降低其炎症因子水平。

中医适宜技术在产妇分娩疼痛管理中的应用进展

该文从分娩疼痛产生机制,中医适宜技术应用于分娩疼痛管理的理论基础及方式进行综述,分析中医适宜技术在减轻产妇分娩疼痛、增加舒适感方面的应用优势,探讨存在的不足,提出对未来的展望,为今后的研究和临床护理实践提供参考。

中药封包联合针刺运动治疗肩周炎临床观察

目的 评估中药封包联合针刺运动治疗肩周炎的临床疗效。方法 选取2021年9月—2022年12月来开封市中医院颈肩腰腿痛科就诊的80例肩周炎患者,随机分为对照组和观察组各40例。对照组给予中药封包及针刺治疗,观察组在对照组治疗的基础上给予针刺运动治疗,观察2组患者的临床疗效,通过视觉模拟评分(VAS)和Constant-Murley肩关节功能(CMS)评分,评估2组患者治疗前后肩关节疼痛和肩关节功能的变化情况。结果 观察组治愈率、总有效率均高于对照组(P<0.05);2组治疗后VAS评分低于治疗前(P<0.05),CMS评分高于治疗前(P<0.05),且观察组评分改善均优于对照组(P<0.05)。结论 中药封包联合针刺运动治疗肩周炎的疗效显著、安全可靠。

中药膏摩治疗腰椎间盘突出症1例的护理

腰椎间盘突出症是骨科常见疾病,下腰痛是患者就诊的主要症状。中医外治疗法缓解腰椎间盘突出症患者疼痛症状效果明确。本文回顾中药膏摩治疗1例腰椎间盘突出综合症患者的效果,总结护理经验。通过对患者精准的护理评估,明确患者的护理目标,在常规护理和健康宣教的基础上,通过实施中药膏摩技术,能够有效改善患者疼痛与下肢无力症状。中药膏摩治疗腰椎间盘突出症效果明确,且不良反应少,易于患者接受。

火龙罐技术联合中药封包疗法在腰腿疼痛患者中的应用

目的探讨火龙罐技术联合中药封包疗法在腰腿疼痛患者中的应用。方法选取2020年1月至2022年9月赣南医学院附属兴国医院收治的66例腰腿疼痛患者为研究对象,采用随机数字表法分为对照组与观察组,每组33例。对照组采用常规药物治疗,观察组采用火龙罐技术联合中药封包疗法。两组治疗1个月比较两组临床疗效、中医证候积分、疼痛程度、恢复情况及生活质量。结果观察组总有效率为90.90%高于对照组的69.70%,差异有统计学意义(P<0.05);两组治疗1个月针刺、痛处拒按、夜间加重、腰部僵硬、活动受限等证候积分低于就诊时,差异有统计学意义(P<0.05),且观察组针刺、痛处拒按、夜间加重、腰部僵硬、活动受限等证候积分低于对照组,差异有统计学意义(P<0.05);两组治疗1个月疼痛数字评分法(NRS)、疼痛强度(PPI)评分低于就诊时,且观察组NRS、PPI评分低于对照组,差异有统计学意义(P<0.05);两组治疗1个月Oswestry功能障碍指数(ODI)评分低于就诊时、PPI评分高于就诊时,且观察组ODI评分低于对照组,PPI评分高于对照组,差异有统计学意义(P<0.05);两组治疗1个月躯体功能、心理功能、社会功能、物质生活功能评分高于就诊时,且观察组躯体功能、心理功能、社会功能、物质生活功能评分高于对照组,差异有统计学意义(P<0.05)。结论腰腿疼痛患者采用火龙罐技术联合中药封包疗法,可有效改善临床症状,减轻疼痛促进腰腿功能恢复,有利于提高生活质量。

复方中草药香包吸入改善大学生痛经的随机对照研究

目的探讨吸入复方中草药香包改善大学生寒凝血瘀型痛经的疗效及安全性。方法将100名寒凝血瘀型痛经大学生采用分层随机分组法分为对照组和试验组各50名。对照组给予健康教育和安慰剂香包吸入,试验组给予健康教育和复方中草药香包吸入,每晚睡觉时将香包悬挂于侧墙且距鼻30 cm处,持续3个月经周期。结果对照组46名、试验组48名大学生完成本研究。组间比较,干预后腹痛视觉模拟量表、Cox痛经症状评分表、疼痛灾难化量表评分及疗效差异有统计学意义(均P<0.05);两组在研究过程中均未报告不良反应。结论复方中草药香包吸入有利于减轻寒凝血瘀型痛经大学生腹痛程度、缓解痛经症状、降低疼痛灾难化水平。

中药封包联合电磁波治疗仪在腹部外科手术后促进肠功能恢复中的应用

目的探讨中药封包联合电磁波治疗仪在腹部外科手术后促进肠功能恢复中的应用效果。方法选取2020年12月至2022年12月赣州市肿瘤医院收治的90例行腹部外科手术患者为研究对象,按照随机数字表法分为对照组(45例)与观察组(45例),对照组采用中药封包干预,观察组采用中药封包联合电磁波治疗仪干预,比较两组患者胃肠功能恢复情况、腹胀严重程度、住院时间、住院费用及满意度。结果观察组首次排气、肠鸣音恢复及排便时间均短于对照组,差异有统计学意义(P<0.05)。两组患者肠粘连发生率比较,差异无统计学意义(P>0.05)。观察组腹胀严重程度轻于对照组,差异有统计学意义(P<0.05)。观察组平均住院时间短于对照组,平均住院费用低于对照组,差异有统计学意义(P<0.05)。观察组总满意度(95.56%)高于对照组(77.78%),差异有统计学意义(P<0.05)。结论中药封包联合电磁波治疗仪可有效改善患者胃肠功能,恢复其营养状况,减轻腹胀症状,减少肠粘连发生,提高满意度,值得推广。